Catheter Ablation vs Drug Therapy in Patients With Atrial Fibrillation and Nonmodifiable Recurrence Risk Factors
JAMA Network Open · 2025
DOI: 10.1001/jamanetworkopen.2025.28124 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2025. Verfasst von Zhen Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Anti-Arrhythmia Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Large-scale randomized studies evaluating the impact of catheter ablation on cardiovascular prognoses across different atrial fibrillation (AF) recurrence risk profiles are lacking.
Objective
To investigate the benefits of catheter ablation in patients with varying numbers of nonmodifiable recurrence risk factors (NMRRFs). Design, Setting, and Participants This study was a post hoc subanalysis of the multinational, multicenter, open-label Catheter Ablation vs Anti-Arrhythmic Drug Therapy for Atrial Fibrillation (CABANA) randomized clinical trial, for which enrollment occurred from November 2009 to April 2016, with follow-up until December 31, 2017. Individuals with AF and at least 1 stroke risk factor were recruited in the CABANA trial. Only those with complete NMRRF data were included in this secondary analysis. Data were analyzed from November 1, 2023, to May 12, 2025. Exposure Patients were categorized into 2 subgroups based on their number of NMRRFs (<3 or ≥3 risk factors). Main Outcomes and Measures The primary end point of the CABANA trial was death, disabling stroke, serious bleeding, or cardiac arrest. Four NMRRFs were examined: AF duration more than 1 year, persistent or long-standing persistent AF, age older than 65 years, and female sex. Multivariable Cox proportional hazards regression models with adjustment were performed to investigate the benefit of ablation in each subgroup.
Results
In total, 2185 patients (median age, 67.0 years [IQR, 62.0-72.0 years]; 1373 males [62.8%]) with complete NMRRF data were included. Of these patients, 1100 (50.3%) were randomized to receive catheter ablation and 1085 (49.7%) were randomized to receive drug therapy. Most patients (1469 [67.2%]) had fewer than 3 NMRRFs, while 716 (32.8%) had 3 or more. In patients with fewer than 3 NMRRFs, catheter ablation reduced the primary end point (adjusted hazard ratio [AHR], 0.59 [95% CI, 0.41-0.86]). However, the difference was not significant in those with 3 or more NMRRFs (AHR, 1.55 [95% CI, 0.93-2.58]). The interaction between the primary end point and the NMRRF category was significant ( P for interaction = .003). Across all NMRRF groups, ablation did not reduce all-cause mortality (<3 NMRRFs: AHR, 0.65 [95% CI, 0.41-1.02] and ≥3 NMRRFs: AHR, 1.23 [95% CI, 0.66-2.33]) but decreased AF recurrence (<3 NMRRFs: AHR, 0.46 [95% CI, 0.40-0.52] and ≥3 NMRRFs: AHR, 0.58 [95% CI, 0.49-0.69]) and improved quality of life throughout follow-up for symptom frequency (<3 NMRRFs: −1.63 [95% CI, −2.18 to −1.07] and ≥3 NMRRFs: −1.15 [95% CI, −1.98 to −0.31]). Conclusions and Relevance In this secondary analysis of the CABANA randomized clinical trial, the findings suggest that catheter ablation yielded significant cardiovascular benefits in patients with AF with fewer than 3 NMRRFs compared with drug therapy. This study lays the foundation for more personalized AF management, potentially optimizing resource allocation and influencing the direction of research and clinical practice in this field. Trial Registration ClinicalTrials.gov Identifier: NCT00911508
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
- Engineering Research Center of Medical Devices for Cardiovascular Diseases, Ministry of Education, Beijing, China.
- National Clinical Research Center for Cardiovascular Diseases, Beijing, China.
Zitieren
APA
Wang, Z., Wu, Y., Jiang, C., He, L., Zhou, N., Sang, C., Dong, J., & Ma, C. (2025). Catheter Ablation vs Drug Therapy in Patients With Atrial Fibrillation and Nonmodifiable Recurrence Risk Factors. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.28124
Vancouver
Wang Z, Wu Y, Jiang C, He L, Zhou N, Sang C, et al. Catheter Ablation vs Drug Therapy in Patients With Atrial Fibrillation and Nonmodifiable Recurrence Risk Factors. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.28124
BibTeX
@article{Wang2025,
author = {Wang, Zhen and Wu, Yanfang and Jiang, Chao and He, Liu and Zhou, Ning and Sang, Caihua and Dong, Jianzeng and Ma, Changsheng},
title = {Catheter Ablation vs Drug Therapy in Patients With Atrial Fibrillation and Nonmodifiable Recurrence Risk Factors},
journal = {JAMA Network Open},
year = {2025},
doi = {10.1001/jamanetworkopen.2025.28124}
}
EUVIMED